Tango Therapeutics, Inc. Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGX

Clasificación en acciones #4542
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Precio por acción
$27.18
Última sincronización: 2026-07-31
Capitalización bursátil
$3.38B
Cambio (1 día)
-1.41%
Cambio (1 año)
197.05%
País
US
Comercio Tango Therapeutics, Inc. (TNGX)

Categoría

Healthcare
Historial de rendimiento por dividendo de Tango Therapeutics, Inc. (TNGX)
Rendimiento por dividendo (TTM) de Tango Therapeutics, Inc. (símbolo bursátil: TNGX) al 2023-12-31: 0.00%
Rendimiento promedio por dividendo de los últimos 5 años: 0.00%
Historial de rendimiento por dividendo de Tango Therapeutics, Inc. (TNGX) desde 2019 hasta 2026
Rendimiento por dividendo al final de cada año (TTM)
Año Rendimiento por dividendo Cambiar
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
Rendimientos por dividendo (TTM) de empresas similares o competidoras
Empresa Rendimiento por dividendo País
0.00%
US
0.00%
US
2.17%
AU
0.00%
CH
0.00%
NL